Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.797
Sell
RSI(14)
32.713
Neutral
STOCH(KDJ)(9,3,3)
7.431
Oversold
ATR(14)
0.954
Low Volatility
CCI(14)
-83.727
Neutral
Williams %R
93.182
Oversold
TRIX(12,20)
-0.308
Sell
StochRSI(14)
70.358
Buy
Search
Sanofi SA
SNYAdd to Watchlist
42.930USD
+0.070+0.16%
Market hours （ET）Quotes delayed by 15 min
103.79BMarket Cap
11.89P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Sanofi SA
Currency: USD Updated: 2026-05-12Key Insights
Sanofi SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 57.14.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanofi SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sanofi SA Highlights
StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 17.07% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 52.67B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 11.88, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 225.52M shares, decreasing 13.87% quarter-over-quarter.
Held by Richard Pzena
Star Investor Richard Pzena holds 19.09K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.04.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
57.144
Target Price
+31.94%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-12The current financial score of Sanofi SA is 7.35, ranking 112 out of 156 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 13.16B, representing a year-over-year increase of 17.99%, while its net profit experienced a year-over-year increase of 4.04%.
Score
Financials
6.49
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.76
Operational Efficiency
10.00
Growth Potential
9.90
Shareholder Returns
7.59
Sanofi SA's Company Valuation
Currency: USD Updated: 2026-05-12The current valuation score of Sanofi SA is 5.82, ranking 138 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 11.88, which is 170.41% below the recent high of 32.11 and 6.81% above the recent low of 11.07.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 81/156
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-12The current earnings forecast score of Sanofi SA is 8.00, ranking 58 out of 156 in the Pharmaceuticals industry. The average price target is 58.58, with a high of 74.67 and a low of 56.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
57.144
Target Price
+31.94%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Sanofi SA
SNY
10
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-12The current price momentum score of Sanofi SA is 6.65, ranking 103 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 46.83 and the support level at 40.67, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
43.124
Sell
MA10
44.102
Sell
MA20
45.650
Sell
MA50
45.726
Sell
MA100
46.658
Sell
MA200
47.823
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-12The current institutional shareholding score of Sanofi SA is 3.00, ranking 95 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.34%, representing a quarter-over-quarter decrease of 6.40%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 56.49M shares, representing 2.34% of shares outstanding, with 19.26% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Managed Account Advisors LLC
Invesco Advisers, Inc.
Mondrian Investment Partners Ltd.
Putnam Investment Management, L.L.C.
Federated Hermes Investment Counseling
Envestnet Asset Management, Inc.
Parametric Portfolio Associates LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-05-12The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sanofi SA is 9.65, ranking 7 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.32
VaR
+2.25%
240-Day Maximum Drawdown
+18.82%
240-Day Volatility
+26.55%
Return
Best Daily Return
60 days
+3.73%
120 days
+3.73%
5 years
+8.06%
Worst Daily Return
60 days
-5.92%
120 days
-5.92%
5 years
-19.13%
Sharpe Ratio
60 days
-1.48
120 days
-1.65
5 years
+0.11
Risk Assessment
Maximum Drawdown
240 days
+18.82%
3 years
+28.48%
5 years
+34.88%
Return-to-Drawdown Ratio
240 days
-0.93
3 years
-0.24
5 years
-0.09
Skewness
240 days
-1.14
3 years
-2.42
5 years
-1.60
Volatility
Realised Volatility
240 days
+26.55%
5 years
+26.03%
Standardised True Range
240 days
+2.14%
5 years
+2.11%
Downside Risk-Adjusted Return
120 days
-220.45%
240 days
-220.45%
Maximum Daily Upside Volatility
60 days
+22.38%
Maximum Daily Downside Volatility
60 days
+21.02%
Liquidity
Average Turnover Rate
60 days
+0.29%
120 days
+0.27%
5 years
--
Turnover Deviation
20 days
+3.62%
60 days
+35.33%
120 days
+26.53%
Peer Comparison
Pharmaceuticals
Sanofi SA
SNY
6.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.10 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
